Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 11, 2013, Pages 1240-1246

  Brady, Stefen ^a,b   Squier, Waney ^a   Hilton Jones, David ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885593282     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305690     Document Type: Article

References (27)

1. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996;40:581-6. (Pubitemid 26357882)
2. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-84.
3. Calabrese LH, Mitsumoto H, Chou SM. Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum 1987;30:397-403. (Pubitemid 17080776)
4. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989;112:727-47. (Pubitemid 19151167)
5. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
6. Vershuuren JJ, Van Engelen BGM, Van Der Hoeven J, et al. Inclusion body myositis. In: Emery A.ed Diagnostic criteria for neuromuscular disorders. London: Royal Society of Medicine, 1997:81-4.
7. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31. (Pubitemid 46921056)
8. Van Der Meulen MF, Hoogendijk JE, Moons KG, et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 2001;11:447-51. (Pubitemid 32510004)
9. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008;79:1056-60.
10. Hilton-Jones D, Miller A, Parton M, et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010;20:142-7.
11. Benveniste O, Hilton-Jones D. International workshop on inclusion body myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010;20:414-21.
12. Inclusion body myositis. 188th European Neuromuscular Centre Workshop, December 2011. Organiser Rose, M. Neuromuscular Disord. In press.
13. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-24.
14. Blume G, Pestronk A, Frank B, et al. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997;120:39-45. (Pubitemid 27081259)
15. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009;278:25-9.
16. Dubourg O, Wanschitz J, Maisonobe T, et al. Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 2011;30:103-8.
17. Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967;158:1453-5.
18. Carpenter S, Karpati G, Heller I, et al. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978;28:8-17. (Pubitemid 8272513)
19. Mhiri C, Gherardi R. Inclusion body myositis in French patients. A clinicopathological evaluation. Neuropathol Appl Neurobiol 1990;16:333-44. (Pubitemid 20246016)
20. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208. (Pubitemid 14062666)
21. Van Der Meulen MF, Hoogendijk JE, Jansen GH, et al. Absence of characteristic features in two patients with inclusion body myositis. J Neurol Neurosurg Psychiatry 1998;64:396-8. (Pubitemid 28159851)
22. Rajakulendran S, Parton M, Holton JL, et al. Clinical and pathological heterogeneity in late-onset partial merosin deficiency. Muscle Nerve 2011;44:590-3.
23. Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993;13:256-63. (Pubitemid 23300092)
24. Peng A, Koffman BM, Malley JD, et al. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000;55:296-8. (Pubitemid 30604636)
25. Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 1993;71:351-61. (Pubitemid 23142833)
26. Machado P, Cortese A, Morrow J, et al. The natural history of sporadic inclusion body myositis-an observational longitudinal study. Arthritis Rheum 2012;64: S99-100.
27. Badrising UA, Maat-Schieman M, Van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55:1385-7.